,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2019-01-29 01:42:00,Investor interest in penny stocks is understandable.,0.23989535868167877,0.01504861656576395,0.7450560331344604,neutral,0.2248467355966568
1,2019-01-29 01:42:00,The prospect of getting a slice of a tiny company before it becomes a household name could be a life-changing event akin to winning the lottery.,0.26147621870040894,0.025508113205432892,0.7130156755447388,neutral,0.23596811294555664
2,2019-01-29 01:42:00,"Nevertheless, just like there's a slim chance of winning the lottery, picking a winning penny stock with huge long-term upside is just as improbable.",0.2207319289445877,0.1179933175444603,0.661274790763855,neutral,0.10273861140012741
3,2019-01-29 01:42:00,That doesn't mean winning big in the stock market isn't a possibility.,0.09189506620168686,0.04106292128562927,0.8670420050621033,neutral,0.05083214491605759
4,2019-01-29 01:42:00,"There are plenty of stocks with lots of potential, without the unnecessary risk.",0.2937760651111603,0.009916752576828003,0.6963072419166565,neutral,0.2838593125343323
5,2019-01-29 01:42:00,"Three that you should consider are salesforce.com (NYSE: CRM) , Lexicon Pharmaceuticals (NASDAQ: LXRX) , and NIO (NYSE: NIO) .",0.019761700183153152,0.007338226772844791,0.9729000926017761,neutral,0.012423473410308361
6,2019-01-29 01:42:00,Nicholas Rossolillo (salesforce.com): Many penny stocks get overhyped by their shareholders and business management teams alike.,0.02739446610212326,0.9281381368637085,0.044467389583587646,negative,-0.9007436633110046
7,2019-01-29 01:42:00,"In contrast, the co-CEO and founder of enterprise software company Salesforce, Marc Benioff, falls into the enthusiastic-and-excitable camp -- but there's an actual track record there to back up the attitude.",0.14022675156593323,0.16183993220329285,0.6979332566261292,neutral,-0.02161318063735962
8,2019-01-29 01:42:00,Consider: Salesforce has been consistently growing its revenue well into the double digits since it went public in 2004.,0.9396153688430786,0.014732318930327892,0.04565224424004555,positive,0.9248830676078796
9,2019-01-29 01:42:00,"Over that period of time, the stock has returned an astonishing 3,300% .",0.9321209788322449,0.0198476854711771,0.04803134500980377,positive,0.9122732877731323
10,2019-01-29 01:42:00,"Though the company now has a market cap of $113 billion, there's still plenty of room for further growth.",0.8059584498405457,0.013214041478931904,0.1808275282382965,positive,0.7927443981170654
11,2019-01-29 01:42:00,That's because the software provider is still growing at a better-than-20%-per-year clip.,0.938461184501648,0.016315748915076256,0.045223042368888855,positive,0.922145426273346
12,2019-01-29 01:42:00,"Through in-house development and strategic acquisition of smaller peers , Salesforce is still very much in growth mode.",0.903427004814148,0.012244856916368008,0.08432815223932266,positive,0.8911821246147156
13,2019-01-29 01:42:00,"During the third-quarter 2018 earnings report, Benioff said he sees years of expansion ahead as the economy -- especially the digital economy -- continues to evolve and changes how businesses operate.",0.8193677663803101,0.012166840024292469,0.16846533119678497,positive,0.8072009086608887
14,2019-01-29 01:42:00,"That plays right into the hand of Salesforce, one of the pioneers of cloud-based services and customer-centric, data-driven software.",0.2683405876159668,0.009183858521282673,0.7224755883216858,neutral,0.259156733751297
15,2019-01-29 01:42:00,"As a high-growth endeavor, Salesforce stock can be volatile, but investors interested in penny stocks are used to that already.",0.14231204986572266,0.12826257944107056,0.7294253706932068,neutral,0.0140494704246521
16,2019-01-29 01:42:00,"However, for those willing to buy in and hold for the long haul, this software maker could be a lot bigger than it is now -- especially as the company eventually transitions out of investment-and-growth mode and into profitability mode.",0.8172237277030945,0.017220234498381615,0.16555598378181458,positive,0.8000034689903259
17,2019-01-29 01:42:00,"Chuck Saletta (Lexicon Pharmaceuticals): The lure of penny stocks comes from the potential of high returns, assuming everything goes perfectly for the speculator buying those shares.",0.2747132480144501,0.012867812998592854,0.7124189138412476,neutral,0.2618454396724701
18,2019-01-29 01:42:00,"The problem, though, is that most penny stocks wind up being manipulated by scammers -- assuming the underlying business is legitimate in the first place.",0.03426831588149071,0.5896092057228088,0.3761225640773773,negative,-0.5553408861160278
19,2019-01-29 01:42:00,"There are times, however, when a legitimate business is at a crossroads, where success could mean a real boost to its operations, while failure could mean a whole heap of trouble.",0.44601884484291077,0.27858778834342957,0.27539342641830444,positive,0.1674310564994812
20,2019-01-29 01:42:00,"For investors willing to take a calculated risk despite the potential for a substantial loss, Lexicon Pharmaceuticals looks like it's at that crossroads right now.",0.36262544989585876,0.016333768144249916,0.6210408210754395,neutral,0.3462916910648346
21,2019-01-29 01:42:00,"Lexicon Pharmaceuticals' shares recently touched a 52-week low after news that a Food and Drug Administration advisory committee deadlocked on whether to recommend approval for its new diabetes drug, Zynquista.",0.031134340912103653,0.9447726607322693,0.0240930262953043,negative,-0.9136382937431335
22,2019-01-29 01:42:00,"Ultimate approval of the drug would provide a boost to Lexicon, which currently only has one approved product on the market.",0.9408843517303467,0.01616710238158703,0.04294861480593681,positive,0.9247172474861145
23,2019-01-29 01:42:00,"That approved product, Xermelo -- a treatment for carcinoid syndrome diarrhea -- provides some revenue, but not enough to cover Lexicon's total costs of research and operations.",0.2993069291114807,0.5508034825325012,0.14988958835601807,negative,-0.2514965534210205
24,2019-01-29 01:42:00,"With the committee's deadlock on Zynquista, it is unclear whether the FDA overall will approve the compound, reject it entirely, or send it back for more testing or other review.",0.042392101138830185,0.21064765751361847,0.7469602227210999,neutral,-0.16825555264949799
25,2019-01-29 01:42:00,The central issue that needs to be addressed is that the risk of diabetic ketoacidosis appears higher for patients on Zynquista than for those on a placebo.,0.2933798134326935,0.222242534160614,0.48437759280204773,neutral,0.07113727927207947
26,2019-01-29 01:42:00,"The question is whether the FDA believes patient education and monitoring are sufficient to warrant approval, or other remediation might be needed.",0.10344727337360382,0.013525661081075668,0.8830270767211914,neutral,0.08992160856723785
27,2019-01-29 01:42:00,"The FDA has an action date for Zynquista of March 22, so investors are likely to learn the company's next steps in the not-too-distant future.",0.1468396633863449,0.009921390563249588,0.8432390093803406,neutral,0.13691827654838562
28,2019-01-29 01:42:00,"Between now and then, though, investors otherwise tempted by penny stocks might instead consider a position in Lexicon Pharmaceuticals for an alternative with a legitimate chance at success.",0.49646446108818054,0.03188076242804527,0.4716547429561615,positive,0.46458369493484497
29,2019-01-29 01:42:00,"In Lexicon's case, the risks are a lot clearer, and the potential benefits come from a real company with real products and a clear inflection point ahead of it.",0.6909486651420593,0.012875700369477272,0.29617565870285034,positive,0.678072988986969
30,2019-01-29 01:42:00,"Daniel Miller (NIO): Investors who are eyeballing penny stocks are lured in by the wild upside potential, and are either willing to accept massive risk or are ignorant of the risk.",0.3918742835521698,0.0383760966360569,0.569749653339386,neutral,0.3534981906414032
31,2019-01-29 01:42:00,"Personally, I think avoiding penny stocks entirely seems like a good bet.",0.09948176145553589,0.02209470607340336,0.8784235119819641,neutral,0.07738705724477768
32,2019-01-29 01:42:00,"But if you're willing to accept risk for potential massive upside, a company often called ""China's Tesla "" is one to consider: NIO.",0.11523202061653137,0.01725957728922367,0.8675083518028259,neutral,0.09797244518995285
33,2019-01-29 01:42:00,NIO is a leading manufacturer of premium electric vehicles in China; there are a number of reasons for optimism about its future potential.,0.6679231524467468,0.010536198504269123,0.32154062390327454,positive,0.6573869585990906
34,2019-01-29 01:42:00,"One reason to remain optimistic, especially in the near term, is that it's based in, and sells in, China -- so it isn't negatively impacted by the ongoing trade tensions between the U.S. and China.",0.3761698305606842,0.02413279563188553,0.5996974110603333,neutral,0.3520370423793793
35,2019-01-29 01:42:00,"Another reason is that NIO has an incredible brand image in China, even if it's relatively unheard-of in the States.",0.6026610732078552,0.013251924887299538,0.38408708572387695,positive,0.5894091725349426
36,2019-01-29 01:42:00,"In fact, in late 2017, NIO presented its first ""NIO Day"" to unveil the ES8 (an electric SUV) -- and it drew over 110 million views, more than the 103.4 million TV viewers for Super Bowl LII a few weeks later.",0.8666058778762817,0.018787460401654243,0.11460662633180618,positive,0.8478184342384338
37,2019-01-29 01:42:00,"And just over a month ago, NIO unveiled its all-new ES6 as an upscale five-passenger SUV that should continue momentum from the ES8.",0.866599977016449,0.013962386175990105,0.11943762749433517,positive,0.8526375889778137
38,2019-01-29 01:42:00,"NIO has a superb brand image in China, exceeded its 2018 sales guidance, and has momentum with its all-new ES6 launch -- but it's the bigger picture that should have investors excited.",0.9312942624092102,0.01891164854168892,0.049794115126132965,positive,0.9123826026916504
39,2019-01-29 01:42:00,"Cleaning up China's massive pollution problems is one of the government's top priorities, and as the country pushes for cleaner vehicles, NIO is well-positioned to sell its premium vehicles to an expanding middle and upper class of consumers.",0.8389094471931458,0.012326184660196304,0.14876432716846466,positive,0.8265832662582397
40,2019-01-29 01:42:00,"Yes, NIO has massive upside in the decades ahead, as China works through its pollution problems and becomes a hub for electric and driverless vehicle development.",0.8820332288742065,0.01384227629750967,0.10412456840276718,positive,0.8681909441947937
41,2019-01-29 01:42:00,But it also has risks.,0.08115904033184052,0.03342317044734955,0.8854177594184875,neutral,0.04773586988449097
42,2019-01-29 01:42:00,"The company is still unprofitable, and competition is surely to heat up in the years ahead, as Tesla and others increase their presence in China.",0.3794187605381012,0.17978966236114502,0.4407915472984314,neutral,0.19962909817695618
43,2019-01-29 01:42:00,"That said, NIO's upside is real, and it's far less risky than speculative penny stocks.",0.23734994232654572,0.024759836494922638,0.7378902435302734,neutral,0.21259009838104248
44,2019-01-29 01:42:00,"10 stocks we like better than Salesforce.com

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen.",0.12068876624107361,0.033474430441856384,0.8458368182182312,neutral,0.08721433579921722
45,2019-01-29 01:42:00,"After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.",0.8087436556816101,0.0373060368001461,0.15395022928714752,positive,0.7714376449584961
46,2019-01-29 01:42:00,"*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Salesforce.com wasn't one of them!",0.23128540813922882,0.016336174681782722,0.7523783445358276,neutral,0.21494923532009125
47,2019-01-29 01:42:00,That's right -- they think these 10 stocks are even better buys.,0.8146857619285583,0.02307075634598732,0.16224350035190582,positive,0.7916150093078613
48,2019-01-29 01:42:00,Click here to learn about these picks!,0.0694708302617073,0.055800698697566986,0.8747285008430481,neutral,0.01367013156414032
49,2019-01-29 01:42:00,Chuck Saletta has no position in any of the stocks mentioned.,0.012221570126712322,0.0506555400788784,0.9371229410171509,neutral,-0.038433969020843506
50,2019-01-29 01:42:00,Daniel Miller has no position in any of the stocks mentioned.,0.009968601167201996,0.043199457228183746,0.9468319416046143,neutral,-0.03323085606098175
51,2019-01-29 01:42:00,Nicholas Rossolillo owns shares of Salesforce.com and TSLA.,0.01545210275799036,0.0093962661921978,0.9751515984535217,neutral,0.006055836565792561
52,2019-01-29 01:42:00,The Motley Fool owns shares of and recommends Salesforce.com and TSLA.,0.028254495933651924,0.02043066918849945,0.9513148665428162,neutral,0.007823826745152473
53,2019-01-29 01:42:00,The Motley Fool has a disclosure policy .,0.016547108069062233,0.01730392687022686,0.9661489725112915,neutral,-0.0007568188011646271
54,2019-01-29 01:42:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
